MAPT and Mental deterioration: The behavioral changes captured by MBI combined with the neurobiological validation that is provided by the amyloid, tau and NfL biomarkers may provide a sensitive approach for detecting and monitoring the individuals at risk for cognitive decline, even irrespective of their cognitive performance.